



# European GMPs and the Role of the Qualified Person (QP)

# The Impact of EU Directives and Guidelines on the Supply Chain

Jersey City, NJ (New York City Metro Area), USA – July 8-9, 2014 A conference organised by the ECA Academy and the European QP Association

### **Speakers**

**Richard M. Bonner** Chairman of the ECA Foundation and the European QP Association

Dr Susanne Ding Boehringer Ingelheim

FDA Speaker (invited)

**Dr Rainer Gnibl** *EU-GMP Inspectorate, Germany* 

**Tor Gråberg** Medical Products Agency, Sweden

**Dr Bernd Renger** Immediate Past Chair of the European QP Association, Germany

Mark Tucker, Ph.D form. FDA Investigator and Compliance Officer, USA

### **Highlights:**

### **Understand European GMPs**

- The European Pharmaceutical Legislation
- EU GMP Update
- Import/ Export
- EU PQR versus US APR
- The US Quality Unit versus the EU QP

### Understand the Role of the QP

- Duties and Responsibilities
- The EU Discretion Paper and the Release of Batches
- Supply Chain and Supplier Qualification

Plus: Clinical Trial Supplies: IMP Handling in Europe and the Role of the QP

### The Role of PIC/S in a globalising World

The View of the FDA

Delegates' Voices:

- "The chemistry between speakers and delegates was great."
- "Very interactive conference, very informative with real life examples."
- "Great broad coverage on topics relating to the QP."
- 'I really enjoyed a conference that also addresses IMPs ! Thank you!"

Media Partners: "The Gold Sheet" IPQ

### Welcome

Dear Colleagues,



The Pharmaceutical Industry is becoming more global due to international collaborations, mergers and acquisitions and more complex supply chains requiring companies to have a greater understanding of pharmaceutical legislation throughout the world. This is becoming increasingly evident by the

number of non EU professionals contacting the European Compliance Academy and the Qualified Persons Association asking for more and more detailed information about the European GMPs and the unique role and responsibility of the EU QP.

The European Compliance Academy ECA and the European QP Association, recognising this need for further professional knowledge development, intend to support the pharmaceutical industry outside Europe in understanding the European approach and legal framework in this respect. Therefore the QP Association has set up the programme at hand on European GMP requirements and the role of the QP.

Representatives from the authorities as well as QPs and well-known experts will talk about the current issues and share their point of view. Various case studies will be presented and discussed to come up with possible solutions.

Make use of this event by exchanging experiences with your colleagues and by establishing informal contact and networking.

I would like to invite you to this unique opportunity, and I look forward to meeting you.

Best regards,



Richard M Bonner Chairman of the Oualified Person Association

#### Important Information!

The presentations of this conference will be available for download and your print-out 1 week before the conference. You will also receive a USB stick at the conference's registration desk.

Note: there will be no print-outs available during the conference.

### Media Partners:

"The Gold Sheet" The Gold Sheet provides an ansightful analysis to help you comply with U.S. and international pharmaceutical manufacturing QA/QC requirements. To find out more, please see www.pharmamedtechbi.com/publications/ the-gold-sheet.



IPQ's monthly format keeps subscribers "Inside the Global Regulatory Dialogue"™ where the initiatives are being defined

that will reshape the landscape. The IPQ is one of the most important Journals in the GMP and regulatory environment. www.ipqpubs.com.

### Background

Over the past few years the role and duties of the Qualified Person keep increasing in significance and scope. Being the key person in the quality function of a pharmaceutical company, the QP has to consider many issues to fulfil the responsibilities and to comply with the European legislation.

### Objective

This Conference is designed by QPs and international Experts as a forum with focus on sharing information and experience and on discussing the critical areas of European GMPs and the QP's daily work.

### **Target Group**

The Conference has been designed for non-European QA and QCU personnel, upper management functions and authority representatives who want to be informed about the latest development regarding European GMPs and the duties and responsibilities of Qualified Persons.

### **Moderator**

Richard M. Bonner, U.K.

QP and Chairman of the Advisory Boards of the ECA Foundation and the European QP Association.

### About the Organizers

### The ECA Academy



The ECA Academy is a non-profit educational organization and part of the ECA Foundation. The ECA was founded in January 1999 as an independent membership association and is today the leading European association with regard to pharmaceutical Quality Assurance and GMP compli-

ance. Close to 5.000 members from all over Europe and abroad represent more than 60 countries. You will find more at www.gmp-compliance.org.

### The European QP Association



The European Qualified Person (QP) Association was founded in July2006 by the European Compliance Academy's (ECA) Advisory Board Members. With this unique association the ECA wants to provide QPs in Europe with a platform allowing them to exchange their experience, discuss the latest regulatory requirements, to identify and address

difficulties and challenges and to support a harmonised European approach. It currently counts more than 2.000 Qualified Persons as members. More information about the QP Association and a membership application form are available at www.qp-association.eu.

### Part I: Understand European GMPs

### Introduction: The ECA Foundation and the

### European QP Association

Richard M. Bonner

### The European Pharmaceutical Legislation

- Relevant European Pharma- and GMP-regulation
- Prerequisites for EU GMP-compliance
- Agreements between EU and third countries (MRA) and impact on USA
- Exchange of information between competent EU-authorities (EMA compilations of community procedures) and impact on USA
  - Dr Rainer Gnibl

### Plus: EU-GMP Update - what's going on at the Moment

### The View of the FDA

- What does FDA think about the EU QP
- Differences between ICH Q 10 and the US Quality Systems Guidance: why both guidances are out in parallel in the US
- EMA and FDA authority positions with respect to the differing GMPs and role of the QP
  - FDA Speaker (invited)

### Case Study: How we experienced EU GMPs and how we align our Quality Systems

- US GMPs versus EU GMPs
- Responsibilities of Head of the Production and the Head of Quality
   Control
- How to implement policies that will be compliant for EU and US GMPs
- How to certify a batch for the EU market
  - Dr Mark Tucker

#### Import into European Union: Preconditions and GMP-certificate/ MIA

- Requirements for different materials or products
- Who is allowed to import
- Which documents are needed for import
- How to obtain a GMP-certificate (GMP-compliance)
- How to prepare an EU GMP-inspection
- Inspection-procedure and follow-up
- Procedure from applicants import request till placing on the EU-market
  - Dr Rainer Gnibl

### The Role of PIC/S in a globalising World

- PIC and the PIC Scheme
- Current and future activities
- USA as PIC/S member: benefits and challenges
  - Tor Gråberg

### Part II: Understand the Role of the QP

### The Legal and Professional Duties of the Qualified Person

- The role of the QP within the pharmaceutical quality System
- The differences between ICH Q 10 and the US Quality Systems Guidance
- What the QP is responsible for
- Batch certification how is it done?
- The Role of the QP in Contract Manufacturing and Testing
- Comparison between the responsibilities of the Head of the US QCU and the EU QP
- Is there something like a US based QP?
  - Richard M. Bonner

### QP Duties and Responsibilities – individual Member States' Regulations

The different Transformation of Directive 2001/83 into national laws

- Article 49 (2) "minimum conditions of qualification"
- Article 50 "established rights and responsibilities"
- Continual professional development
- The role of professional bodies in the various member states
- Selected examples
- Dr Bernd Renger

### The EU Discretion Paper and the Release of Batches by the QP

European and national Guidance and Expectations on investigating Deviations and OOS Results

- Responsibilities of the QP
- The EMA Reflection paper on "QP Discretion"
- The QP's true margin of discretion
- Selected examples
- Dr Bernd Renger

### EU-PQR versus US-APR

- Goals and technical-terms of EU-PQR
- Critical points
- Practical implementation of EU-PQR
- Comparison between EU- and US-requirements
- PQR and contract manufacturing
  - Dr Rainer Gnibl

### The role of the QP in the Supply Chain and Supplier Qualification

- QP declaration
- Supply Chain oversight
- EU Inspections in the U.S. and the Involvement of the QP
  - Richard M. Bonner

### The US Quality Unit versus the EU QP (Panel Discussion)

• Richard M. Bonner

# Clinical Trial Supplies: IMP Handling in Europe and the Role of the QP

- EU GMP and QP requirements for the release of IMPs
- GMP-GCP Interface
- QP oversight and being a QP in a global environment
- Liability of the IMP QP
- Case studies
  - Dr Susanne Ding

### Welcome Reception

On Tuesday, July 8, 2014, you are cordially invited to a welcome reception after the programme. This is an excellent opportunity to share your experiences with speakers and colleagues from other companies in a relaxed atmosphere.

### **Speakers**



**Richard M. Bonner,** *Chairman of ECA Foundation and the European QP Association, formerly with Eli Lilly* Richard Bonner was a Senior Quality Adviser for Eli Lilly and Company. Mr Bonner is a Qualified Person in Europe,

Chairman of the ECA and of the Qualified Person Association Advisory Board.



**Dr Susanne Ding,** *Boehringer Ingelheim, Germany* As Qualified Person for IMPs at Boehringer Ingelheim Pharma Susanne Ding is in charge of releasing clinic trial samples for the use in clinical studies worldwide since 2005. Prior to that

she worked in Analytical Development including the responsibility as Head of Quality Control. Susanne Ding is co-chair of the IMP Working Group.



**Dr Rainer Gnibl,** *Government of Upper Bavaria, Germany* Dr Rainer Gnibl is EU-GMP inspector in Germany and performs GMP inspections worldwide also on behalf of the European Medicines Agency (EMA).



**Tor Gråberg,** *Swedish Medical Products Agency* Tor Gråberg is Chief Pharmaceutical Inspector and Head of the Drug Inspectorate of the Swedish Medical Products Agency. From 2010 - 2012 he was Chairman of PIC/S

(Pharmaceutical Inspection Co-operation Scheme). Mr. Gråberg is also the Swedish representative within the EMA GMDP Inspection Working Group.



### **Dr Bernd Renger,** Immediate Past Chair European QP Association

Dr Bernd Renger is a member of the ECA Foundation Advisory Board and Immediate Past Chair of the European QP

Association. Since 2011 he is running his own consultancy business. Before that he was VP of Quality Control at Vetter Pharma-Fertigung. He started his career 1977 at Hoechst AG as a research and development chemist. Since then, he has held several quality management positions at Mundipharma, Byk Gulen (now Takeda) and Baxter BioScience.



Mark Tucker, Ph.D, form. FDA Investigator and Compliance Officer, USA

Mark Tucker was Senior Director, GMP Compliance at Genentech Inc., South San Francisco, USA. Before joining

Genentech in 2002, Mark was Director, Investigations Branch at U. S. Food and Drug Administration (FDA). He also served as an Investigator and Compliance Officer with the FDA. He is now a consultant to the pharmaceutical industry.

#### **Date Conference**

Tuesday July 8, 2014, 9.30am – 5.15pm (Registration and breakfast 9.00am – 9.30am) (Welcome Reception 5.15pm – 6.30pm) Wednesday July 9, 2014, 9.00am – 3.30pm (Breakfast 8.30am)

#### Venue

Hyatt Regency Jersey City Two Exchange Place Jersey City, NJ 07302-US Tel.: +1 201 469 4750 Fax:+1 469 4560

The hotel is located on the Hudson River with a view to the Manhattan skyline. It is located near easy transportation and just minutes from New York by ferry or the PATH train. From LaGuardia Airport: 14 miles From Newark Airport: 12 miles

#### **Fees Conference**

ECA Members	Non-ECA Members	Government/Health Authority
US\$ 1,990	US\$ 2,200*	US\$ 750

\* Registration entails free ECA membership for the following two years after the event

The conference fee is payable in advance after receipt of invoice and includes conference documentation, a welcome reception on the first day, breakfast and lunch on both days and all refreshments.

#### Accommodation

The organizers have reserved a limited number of rooms in the conference hotel. Please make your reservation via POG (Personalized Online Group Page). You will receive a reservation link together with your confirmation/invoice. Early reservation is recommended.

#### Registration

Via the reservation form on the back of this program, by e-mail to info@qp-association.eu or by fax to +49 (0) 6221 / 84 44 34. Or you register online at www.qp-association.eu.

#### **Conference language**

The official conference language will be English.

#### **Organisation / Contact**

CONCEPT HEIDELBERG P.O. Box 10 17 64 D-69007 Heidelberg, Germany Phone +49 (0) 62 21/84 44-0 Fax +49 (0) 62 21/84 44 34 E-mail: info@concept-heidelberg.de www.concept-heidelberg.de

#### For questions regarding content:

Mr Wolfgang Schmitt (Operations Director) at +49 (0)62 21 / 84 44 39, or per e-mail at w.schmitt@concept-heidelberg.de. **For questions regarding reservation, hotel, organisation etc:** Ms Marion Grimm (Organisation Manager) at +49 (0) 62 21 / 84 44 18, or per e-mail at grimm@concept-heidelberg.de.

#### **Easy Registration**

**Reservation Form:** () CONCEPT HEIDELBERG P.O. Box 10 17 64 69007 Heidelberg Germany



### European GMPs and the Role of the Qualified Person (QP)

July 8-9, 2014, Jersey City, NJ (New York City Metro Area)

Contact Information					
Title, Last Name, First Name					
Job Title					
Company			Department		
Mailing Address					
City	State/F	Province	Zip+4/Postal Code		
Country					
Phone / Fax			EMail		
<b>1. Registration for Conference</b> (Please check appropriate fee in US \$	<b>e</b>				
ECA Members	Non-ECA Member		Ders		Government / Health Authority
<b>□</b> \$ 1,990		□ \$ 2,200*			<b>\$</b> \$ 750
* Registration entails free ECA member <b>2. Payment by Credit Card</b> (All cards will be charged in US \$)	rship for the following two Please bill my:	D years after the event	□ Master Card	□ VISA	
Total Amount					
Account Number	Expiration Date			C	ard Validation Number (3/4 digits)
Name (exactly as it appears on the card)			Signature		
Billing Address					
City	State/Province		Zip+4/Postal Code		
Country					

#### **General Terms of Business**

General terms of business
If you cannot attend the conference you have two options:
1. We are happy to welcome a substitute colleague at any time.
2. If you have to cancel entirely, we must charge the following processing fees: Cancellation
until 2 weeks prior to the conference 10 % of the registration fee.
until 1 week prior to the conference 50 % of the registration fee.
within 1 week prior to the conference 100 % of the registration fee.
CONCEPT HEIDELBERG reserves the right to change the materials, instructors, or speakers without notice or to cancel an event of the concellance of the concellance of the context will be potified as soon as possible and

## will receive a full refund of fees paid. CONCEPT HEIDELBERG will not be responsible for discount airfare penalties or other costs incurred due to

Terms of payment: Payable in advance with credit card.

**Important:** This is a binding registration and above fees are due in case of cancellation or non-appear-ance. If you cannot take part, you have to inform us in writing. The cancellation fee will then be calculated according to the point of time at which we receive your message. In case you do not appear at the event without having informed us, you will have to pay the full registration fee payable by registration. You are not entitled to participate in the conference until we have received your payment (receipt of payment will act to referred).